Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Gottlieb

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
The Journal of Investigative Dermatology|August 7, 2017
Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis"Kristian Reich, Craig Leonardi, Kim Papp, et al.
Acta Dermato-Venereologica|September 21, 2017
Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term ExtensionAlexandra B Kimball, Thomas Luger, Alice Gottlieb, et al.
Journal of the American Academy of Dermatology|January 28, 2012
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasisNaresh Punwani, Peggy Scherle, Robert Flores, et al.
Journal of the American Academy of Dermatology|March 19, 2011
In response to "Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: risk or opportunity?"Amylynne Frankel, Abby S Van Voorhees, Sylvia Hsu, et al.
RMD Open|January 5, 2018
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1Laura C Coates, Mitsumasa Kishimoto, Alice Gottlieb, et al.
Lancet (London, England)|February 17, 2009
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialAlice Gottlieb, Alan Menter, Alan Mendelsohn, et al.
Rheumatology International|November 15, 2018
Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and EuropeAlice Gottlieb, Jordi Gratacos, Ara Dikranian, et al.
Journal of the American Academy of Dermatology|July 6, 2010
Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasisDanielle Levine, Zeev Even-Chen, Irina Lipets, et al.
Journal of the American Academy of Dermatology|September 24, 2018
A provider global assessment quality measure for clinical practice for inflammatory skin disordersAlice Gottlieb, Nicole Salame, April W Armstrong, et al.
Annals of the Rheumatic Diseases|May 23, 2019
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studiesArthur Kavanaugh, Alice Gottlieb, Akimichi Morita, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
The Journal of Investigative Dermatology|August 7, 2017
Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis"Kristian Reich, Craig Leonardi, Kim Papp, et al.
Acta Dermato-Venereologica|September 21, 2017
Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term ExtensionAlexandra B Kimball, Thomas Luger, Alice Gottlieb, et al.
Journal of the American Academy of Dermatology|January 28, 2012
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasisNaresh Punwani, Peggy Scherle, Robert Flores, et al.
Journal of the American Academy of Dermatology|March 19, 2011
In response to "Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: risk or opportunity?"Amylynne Frankel, Abby S Van Voorhees, Sylvia Hsu, et al.
RMD Open|January 5, 2018
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1Laura C Coates, Mitsumasa Kishimoto, Alice Gottlieb, et al.
Lancet (London, England)|February 17, 2009
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialAlice Gottlieb, Alan Menter, Alan Mendelsohn, et al.
Rheumatology International|November 15, 2018
Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and EuropeAlice Gottlieb, Jordi Gratacos, Ara Dikranian, et al.
Journal of the American Academy of Dermatology|July 6, 2010
Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasisDanielle Levine, Zeev Even-Chen, Irina Lipets, et al.
Journal of the American Academy of Dermatology|September 24, 2018
A provider global assessment quality measure for clinical practice for inflammatory skin disordersAlice Gottlieb, Nicole Salame, April W Armstrong, et al.
Annals of the Rheumatic Diseases|May 23, 2019
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studiesArthur Kavanaugh, Alice Gottlieb, Akimichi Morita, et al.
Pageof 7